Table 5 Relative risk and 95% confidence interval of UGIB according to timing, dose and duration of aspirin.

	Cases (n = 2777)	Controls (n = 5532)	Age‐adjusted RR (95% CI)	Adjusted condition RR (95% CI)*
Aspirin use
Non‐use	1941	4674	Reference	Reference
Current (0–7 days)	746	524	3.5 (3.1 to 4.0)	5.3 (4.5 to 6.3)
Past (8 days and more)	90	334	0.6 (0.5 to 0.8)	0.7 (0.6 to 1.0)
Aspirin dose
Non‐use	1941	4674	Reference	Reference
100 mg	132	185	1.8 (1.4 to 2.2)	2.7 (2.0 to 3.6)
200 mg	126	122	2.5 (2.0 to 3.3)	3.8 (2.7 to 5.2)
300 mg	114	74	3.8 (2.8 to 5.1)	6.1 (4.3 to 8.7)
500 mg	259	112	5.6 (4.4 to 7.0)	7.5 (5.7 to 9.9)
1 g	76	24	7.6 (4.8 to 12.4)	10.4 (6.1 to 17.8)
>1 g	39	7	13.3 (5.9 to 29.8)	21.2 (8.7 to 51.9)
Aspirin duration
Non‐use	1941	4674	Reference	Reference
1–30 days	300	88	8.2 (6.4 to 10.4)	10.2 (7.7 to 13.5)
31–90 days	32	10	7.9 (3.9 to 16.1)	15.8 (6.8 to 36.8)
91–365 days	103	67	3.8 (2.8 to 5.2)	7.4 (5.0 to 11.1)
>1 year	311	359	2.1 (1.8 to 2.5)	3.1 (2.5 to 3.8)

*Adjusted for age, sex, calendar semester, ulcer history, nitrates, anticoagulants, antiplatelets, acid‐suppressing drugs, NSAID and coxib use.

UGIB, upper gastrointestinal bleeding.